Astrazeneca (AZN) Gross Profit (2009 - 2026)

Astrazeneca's Gross Profit history runs 18 years deep, the most recent figure standing at $12.6 billion for Q1 2026.

• In Q1 2026, Gross Profit rose 11.13% year-over-year to $12.6 billion; the TTM figure through Mar 2026 stood at $49.4 billion (up 10.32% YoY), while the FY2025 annual figure was $48.1 billion, up 9.67% from the prior year.
• Gross Profit was $12.6 billion for Q1 2026 at Astrazeneca, up from $12.4 billion in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $12.6 billion in Q1 2026 to a low of $7.8 billion in Q2 2022.
• Historically, Gross Profit has averaged $10.2 billion across 5 years, with a median of $10.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Gross Profit jumped 82.77% in 2022, then grew 1.8% in 2025.
• A 5-year view of Gross Profit shows it stood at $8.3 billion in 2022, then grew by 16.96% to $9.7 billion in 2023, then increased by 25.22% to $12.2 billion in 2024, then rose by 1.8% to $12.4 billion in 2025, then climbed by 1.82% to $12.6 billion in 2026.
• The last three Gross Profit figures came in at $12.6 billion (Q1 2026), $12.4 billion (Q4 2025), and $12.4 billion (Q3 2025), per Business Quant data.